Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
0.8918
+0.0415 (4.88%)
At close: Jun 22, 2026, 4:00 PM EDT
0.8650
-0.0268 (-3.01%)
Pre-market: Jun 23, 2026, 7:40 AM EDT
Traws Pharma Employees
As of December 31, 2025, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$390,429
Profits / Employee
-$1,987,143
Market Cap
13.51M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 0 | - | 4 | 3 |
| Dec 31, 2024 | 7 | -11 | -61.11% | 6 | 1 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Dec 31, 2022 | 17 | 2 | 13.33% | 16 | 1 |
| Dec 31, 2021 | 15 | 3 | 25.00% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| BioLineRx | 24 |
| Jasper Therapeutics | 22 |
| OSR Holdings | 22 |
| IN8bio | 18 |
| SeaStar Medical Holding | 17 |
| BioVie | 13 |
| Cocrystal Pharma | 10 |
TRAW News
- 1 day ago - Traws Pharma provides update on tivoxavir marboxil program - TheFly
- 1 day ago - Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - GlobeNewsWire
- 5 days ago - Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 8 days ago - Traws Pharma downgraded to Neutral from Buy at Ladenburg - TheFly
- 10 days ago - Traws Pharma influenza challenge study deferred following MHRA review - TheFly
- 10 days ago - Traws Pharma Provides Regulatory Update on Influenza Program - GlobeNewsWire
- 25 days ago - Traws Pharma Proxy statement: Proxy filing - Filings
- 25 days ago - Traws Pharma Proxy statement: Proxy filing - Filings